Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LS 301 IT

Next Previous
X
Search
Drug Profile

LS 301 IT

Alternative Names: LS-301-IT

Latest Information Update: 18 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Integro Theranostics
  • Class Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer
  • Preclinical Gynaecological cancer

Most Recent Events

  • 24 Jul 2023 Integro Theranostics plans a phase Ib/II trial for Breast cancer (Diagnosis, In adults, In the elderly) in USA (IV, Injection), in July 2023 (Integro Theranostics pipeline, July 2023) (NCT05900986)
  • 24 Jul 2023 Preclinical trials in Gynaecological cancer (Diagnosis) in USA (IV), prior to July 2023 (Integro Theranostics pipeline, July 2023)
  • 14 Jul 2023 Phase-I/II clinical trials in Breast cancer (Diagnosis) in USA (IV) (NCT05900986)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top